Product launch: SpheriCal® Peptide Low + Small Molecule

Report this content

Polymer Factory are pleased to announce the launch of a new product in the SpheriCal® family. SpheriCal® Peptide Low + Small molecule expands the calibration range of our lowest mass SpheriCal® product down to 250 m/z, making this an ideal standard for researchers with lower mass analytes and MALDI Imaging applications.

This product is now available in our online store here. For more information about the SpheriCal® products or to make an order, please contact us at

About SpheriCal® Peptide Low + Small Molecule

SpheriCal® Peptide Low + Small Molecule covers a calibration range of 250 - 1,600 m/z with 6 calibration signals, expanding the calibration range for the detection of lower mass species.

SpheriCal® is a dendrimer-based MALDI-TOF MS calibration standard providing multiple monodisperse mass signals per kit for efficient, highly accurate calibration. By combining excellent long-term stability with evenly-spaced calibration points, SpheriCal® helps users increase the frequency and quality of their calibrations.  With a shelf life of years and each kit offering at least 100 calibrations, SpheriCal® offers a reliable and accurate calibration across a large mass range, without the shelf-life and storage issues associated with protein or peptide-based systems.

Polymer Factory Sweden AB

Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company’s dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company’s vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company’s dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at